Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024
LONDON, August 18, 2014 /PRNewswire/ --
Opportunities for Leading Companies
Alzheimer's medicine - your guide to technologies, trends and revenues
Where is the Alzheimer's disease treatment market heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2014, helping you stay ahead.
Our 182-page report provides 131 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr. Simon Ridley, Head of Research, Alzheimer's Research UK
- David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
- Elizabeth Edgerly, PhD., Chief Program Officer, The Alzheimer's Association Northern California and Northern Nevada
Many opportunities exist for diagnosis and treatment of Alzheimer's. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead
Discover sales predictions for the world market and submarkets
Along with revenue prediction of the overall world market, you see forecasts to 2024 for these two submarkets:
• Medicines for Alzheimer's disease
• Diagnostics for Alzheimer's (including biomarkers).
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for Alzheimer's disease drugs
How will leading drugs perform to 2024 at world level? Our study predicts individual revenues of three products:
• Namenda
• Aricept
• Exelon
And also three pipeline products:
• Solanezumab
• Gantenerumab
• MK-8931
There you discover how high sales can go. You see what's happening, understanding trends, challenges and opportunities.
Our analysis also breaks the main world forecast into geographical markets.
What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2014.
In addition to analyses of the overall world market, you discover revenue forecasts for 11 leading national markets to 2024:
• US
• Japan
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• China
• Brazil
• Russia
• India
• Rest of the World
There you find potential. Large companies and specialty biopharma and diagnostics firms face many opportunities. Our study explains, assessing developments to help your work.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Leading companies and potential for market growth
Overall world revenue for Alzheimer's disease therapeutics and diagnostics will reach $7.0bn in 2014, our work forecasts. Our new study predicts the market will expand fast, especially beyond 2018. Disease-modifying therapies will transform that market. New drugs hold great potential from 2018 to 2024, given the prevalence of Alzheimer's and needs for more-effective treatments.
Our work shows you what organisation hold greatest potential. See profiles of 14 leading companies, including these:
• Pfizer
• Eisai
• Forest Laboratories
• Lundbeck
• Daiichi Sankyo
• Novartis
• TauRx Therapeutics
• Transtech Pharma
• Eli Lilly
• Amarantus BioScience Holdings, Inc
• Piramal Enterprises
• GE Healthcare
• Navidea
• Diagenic
In general, a company profile gives you the following information:
• Revenue forecasts for Alzheimer's disease drugs from 2014 to 2024
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, collaborations, including alliances, partnerships and joint ventures.
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
What affects producers of those diagnostic tests and medicines?
Our report discusses issues and events affecting that industry and market from 2014, including these:
• Research and development (R&D) - drugs, diagnostic tests, and related technologies
• Disease prevalence - expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines - changes and opportunities.
The study also discusses other aspects of diagnosing and treating Alzheimer's:
• Needs for Alzheimer's treatments
• Drugs and related technologies to transform the market
• Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging
• Diagnostic tests in development
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.
That way, you explore the industry's strengths, weaknesses, opportunities, and threats. You also analyse it through Porter's five forces.
See, then, what the future holds.
How the Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024: Opportunities for Leading Companies report helps you
In summary, our 182-page report gives you the following knowledge:
• Revenue forecast to 2024 for the world Alzheimer's disease therapeutics and diagnostics market and 2 submarkets - Discover the industry's prospects, finding promising places for investment and revenues.
• Revenue forecasts to 2024 for the leading 11 national markets - US, Japan, Germany, France, UK, Italy, Spain, Rest of Europe, Brazil, Russia, China, India, and Rest of the World
• Assessment of 14 leading companies - hear about products, results and strategies including revenue forecasts for Alzheimer's disease drugs to 2024
• Predicted revenues for 3 Alzheimer's disease drugs in the market and 3 promising drugs in the pipeline to 2024 - see potentials of top products and promising products in development.
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies in the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with three leading authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the Alzheimer's disease therapeutics and diagnostics market and leading companies. You find data, trends and predictions. Please order our report now.
Companies Listed in this Report
AbbVie
AC Immune
Acadia Pharmaceuticals
Accera
Actavis
Adamas Pharmceuticals
Affiris
Amarantus BioSciences
Amorphis
Archer Pharmaceuticals
Astex
AstraZeneca
Avanir Pharmaceuticals
Avineuro Pharmaceuticals
Baxter
Bayer
Bayer Schering Pharma
Biogen
bioMerieux
Ceregene
Chiesi Farmaceutici
Cognoptix
Cytos
Daiichi Sankyo
DiaGenic
Eisai
Elan
Eli Lilly
EnVivo Pharmaceuticals
Forest Laboratories
Forum Pharmaceuticals
Foundation Medical Partners
Functional Neuromodulation
GE Healthcare
General Electric
Genervon Biopharmaceuticals
Genesys Capital
GSK
Hisamitsu Pharmaceutical
Humanetics
IBA Molecular
J&J
Janssen Alzheimer Immunotherapy Research & Development
Janssen Pharmaceutical K. K
Kareus Therapeutics
LabCorp
Luminex
Lundbeck
Medtronic
Merck & Co
Merz
Meso Scale Diagnostics
Metabolic Solutions Development Company
MorphoSys
Nanotherapeutics
Navidea
NextGen Sciences
Novartis
Novo Nordisk
Ono Pharmaceutical
OPKO
Ortho Clinical Diagnostics
Otsuka Pharmaceutical
Oxford BioDynamics
Par Pharmaceuticals
Pfizer
Piramal Enterprises
Piramal Imaging
Proteome Sciences
ProteoTech
Proterra
QR Pharma
Quanterix
Raptor Pharmaceutical
Resverlogix
Roche
Roche Diagnostics
Saladax
Sangamo BioSciences
Sanofi
sGC Pharma
Shionogi
Shire
Siemens Medical Solutions USA
Somalogic
Sonexa Therapeutics
Sun Pharma
T3D Therapeutics
Takeda
Targacept
TauRx
Toyama Chemical
Transition Therapeutics
TransTech Pharma
United Biomedical
VIVUS
Wyeth
Other Organisations Mentioned in This Report
Alzheimer's Association International Conference (AAIC)
Alzheimer's Research UK
Assogenerici (Italy)
Cambridge University
Cleveland Clinic Lou Ruvo Center for Brain Health
Dementia UK
French Economic Committee
King's College London
Ministry of Health, Labout and Welfare (MHLW) (Japan)
National Health Services (Italy)
National Health Services (NHS) (UK)
National Institute of Clinical Excellence (NICE)
National Institute of Health (NIH)
The Alzheimer's Association
The Centers for Medicare and Medicaid Services (CMS)
The Central Drug Standard Control Organisation (CDSCO)
The Duke University
The European Commission
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)
The Food and Drug Administration FDA (US)
The Health and Social Care Information Centre
The National Institute of Aging (NIA)
The Supreme Court of Japan
The University of Aberdeen
The University of Cologne
The University of Pittsburgh
Trinity College Dublin
United Nations (UN)
World Health Organisation (WHO)
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44-(0)-20-7336-6100
Share this article